Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received a notice of acceptance from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - The application for Edaravone tablets, with the development code TTYP01, has been officially accepted by the NMPA [1] - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]

Core Viewpoint - Huadong Medicine (000963) announced that its wholly-owned subsidiary, Sino-American Huadong, has had its application for the marketing authorization of Edaravone tablets for the treatment of acute ischemic stroke accepted by the National Medical Products Administration [1] Group 1: Product Development - Edaravone tablets are a new type of free radical scavenger aimed at improving neurological symptoms and functional impairments in stroke patients [1] - Compared to the existing Edaravone injection, the oral tablet form is more convenient for self-administration by patients [1] Group 2: Licensing and Investment - Sino-American Huadong has signed an exclusive licensing agreement with AusBio, acquiring the rights for the development, registration, production, and commercialization of the drug in mainland China and the Hong Kong, Macau, and Taiwan regions [1] - The company has invested approximately 101 million yuan in this project, including an upfront payment of 100 million yuan for project introduction [1]